Primary aldosteronism and lower-extremity arterial disease: a two-sample Mendelian randomization study

Cardiovasc Diabetol. 2023 Dec 20;22(1):352. doi: 10.1186/s12933-023-02086-x.

Abstract

Background and aims: Primary aldosteronism (PA) is an adrenal disorder of autonomous aldosterone secretion which promotes arterial injury. We aimed to explore whether PA is causally associated with lower-extremity arterial disease (LEAD).

Methods: We included 39,713 patients with diabetes and 419,312 participants without diabetes from UK Biobank. We derived a polygenic risk score (PRS) for PA based on previous genome-wide association studies (GWAS). Outcomes included LEAD and LEAD related gangrene or amputation. We conducted a two-sample Mendelian randomization analysis for PA and outcomes to explore their potential causal relationship.

Results: In whole population, individuals with a higher PA PRS had an increased risk of LEAD. Among patients with diabetes, compared to the subjects in the first tertile of PA PRS, subjects in the third tertile showed a 1.24-fold higher risk of LEAD (OR 1.24, 95% CI 1.03-1.49) and a 2.09-fold higher risk of gangrene (OR 2.09, 95% CI 1.27-3.44), and 1.72-fold higher risk of amputation (OR 1.72, 95% CI 1.10-2.67). Among subjects without diabetes, there was no significant association between PA PRS and LEAD, gangrene or amputation. Two-sample Mendelian randomization analysis indicated that genetically predictors of PA was significantly associated with higher risks of LEAD and gangrene (inverse variance weighted OR 1.20 [95% CI 1.08-1.34]) for LEAD, 1.48 [95% CI 1.28-1.70] for gangrene), with no evidence of significant heterogeneity or directional pleiotropy.

Conclusions: Primary aldosteronism is genetically and causally associated with higher risks of LEAD and gangrene, especially among patients with diabetes. Targeting on the autonomous aldosterone secretion may prevent LEAD progression.

Keywords: Causal relationship; Diabetes; Lower-extremity arterial disease; Mendelian randomization; Primary aldosteronism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aldosterone
  • Diabetes Mellitus*
  • Gangrene
  • Genetic Risk Score
  • Genome-Wide Association Study
  • Humans
  • Hyperaldosteronism* / diagnosis
  • Hyperaldosteronism* / epidemiology
  • Hyperaldosteronism* / genetics
  • Lower Extremity
  • Mendelian Randomization Analysis
  • Polymorphism, Single Nucleotide
  • Vascular Diseases*

Substances

  • Aldosterone